Brokers: How is the 2025 FDA drug pipeline affecting your self-insured clients?

NEW BLOG

The 2025 FDA Drug Pipeline: Implications for Self-Insured Employer Groups

The FDA drug pipeline is brimming with promising new treatments that offer hope for improved patient outcomes, but also present cost challenges for self-insured plans.

Read More

INDUSTRY NEWS

• The impact of obesity on employer health costs.
• Rx transparency and an analysis of the RxDC.
• Utilization management - why it's broken and how to fix it.
• Recall of Potassium Chloride Injection due to mislabeling.
• Voluntary recall of one lot of Fentanyl Transdermal System.

Explore the New Design

Take a look at our newly designed website, updated for easier navigation.